Phase 3 Study of L606 in Patients with PH-ILD Shows Safety and Efficacy Potential
A Phase 3 study is evaluating the safety and efficacy of L606 in patients with pulmonary hypertension due to interstitial lung disease.
Asset / Drug
Drug and asset intelligence for Pulmonology with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.